<< Back
Valeant Completes Syndication of Senior Secured Term Loan B Facility

MISSISSAUGA, Ontario, Feb. 13, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today announced the successful syndication of a $600 million senior secured Tranche B Term Loan facility under its existing senior secured credit facilities to fund repayment of certain outstanding amounts under its existing revolving facility and for general corporate purposes, including acquisitions.  The Tranche B Term Loans will mature in 2019 and have terms that are customary for this type of financing. The Tranche B Term Loans bear interest at a rate per annum equal to, at Valeant's option, a base rate or a LIBO rate plus an applicable margin. The initial interest rate for the Tranche B Term Loans is the LIBO rate plus 2.75% per annum. The facility closed on February 13, 2012.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International, Inc.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Valeant Pharmaceuticals International, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.